Sign In
Buy CBIO
$17.98
+0.98 (+5.73%)
At Close: Jun 03, 2026
Catalyst Biosciences Announces Poster Presentation at the 62nd Annual American Society of Hematology Conference
09:00am, Thursday, 05'th Nov 2020
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced a trials in progress poster presentation on Marzeptacog alfa (activated) – or
Catalyst Biosciences Reports Third Quarter 2020 Operating & Financial Results and Provides a Corporate Update
08:00am, Thursday, 05'th Nov 2020
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the third quarter ended September 30, 2
Catalyst Biosciences to Present at Stifel 2020 Virtual Healthcare Conference
08:00am, Tuesday, 03'rd Nov 2020
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that Nassim Usman, Ph.D., president and chief executive officer, and Clinton M
National Hemophilia Foundation Revises Treatment Guidelines for Factor 1 Deficiency to Include Octapharma’s fibryga®
12:00am, Wednesday, 07'th Oct 2020
The National Hemophilia Foundation has revised its treatment recommendations for congenital fibrinogen (Factor 1) deficiency to include fibryga®.
Catalyst Biosciences Reports Second Quarter 2020 Operating & Financial Results and Provides a Corporate Update
12:00pm, Thursday, 06'th Aug 2020
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the second quarter ended June 30, 2020
Catalyst Biosciences Presents Data at the International Society for Thrombosis and Haemostasis (ISTH) Virtual Congress
12:00pm, Monday, 13'th Jul 2020
Subcutaneous marzeptacog alfa (activated) (MarzAA) rapidly achieves and maintains therapeutic levels Data confirm Phase 3 study design to treat acute bleeding events in.
Does Catalyst Biosciences' (NASDAQ:CBIO) Share Price Gain of 34% Match Its Business Performance?
01:48pm, Thursday, 09'th Jul 2020
It might be of some concern to shareholders to see the Catalyst Biosciences, Inc. (NASDAQ:CBIO) share price down 24...
Hedge Funds Still Very Bullish On Catalyst Biosciences Inc (CBIO)
01:28am, Wednesday, 08'th Jul 2020
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes
Two Sigma Advisers LP Increases Stock Position in Catalyst Biosciences Inc (NASDAQ:CBIO)
04:50am, Monday, 06'th Jul 2020
Two Sigma Advisers LP raised its holdings in Catalyst Biosciences Inc (NASDAQ:CBIO) by 39.2% during the 1st quarter, Holdings Channel reports. The firm owned 193,100 shares of the biopharmaceutical co
Catalyst Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:48pm, Wednesday, 01'st Jul 2020
The stock option was granted as an inducement material to Mr. Musil’s entering into employment with Catalyst in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option was granted outside
Catalyst Biosciences Announces Presentations at the International Society on Thrombosis and Haemostasis
12:00pm, Monday, 29'th Jun 2020
SOUTH SAN FRANCISCO, Calif., June 29, 2020 -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced two presentations at the upcoming International Society on Thrombosis.
Sigue habiendo oportunidades en empresas biotecnológicas
12:00am, Monday, 29'th Jun 2020
Análisis de Acciones por Salva Fuster cubriendo: AXA SA, Volkswagen AG VZO O.N.. Lea los Análisis de Acciones de Salva Fuster en Investing.com.
Catalyst Biosciences Announces Closing of Public Offering of Common Stock
08:05pm, Monday, 22'nd Jun 2020
The gross proceeds to Catalyst from this offering were approximately $30.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Catalyst.
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on InflaRx (IFRX –
